A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT03669640 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
131
Enrollment
INDUSTRY
Sponsor class

Stopped This study was discontinued due to an interim analysis which indicated that ralmitaront was unlikely to meet its primary endpoint.

Conditions

Interventions

Sponsor

Hoffmann-La Roche